Since 1980, APH has provided airport parking, hotels, lounges and travel extras to UK travellers. With nearly four decades of experience and still family owned, we’re the leading independent airport parking company in the UK, now operating over 10,000 spaces and parking more than 300,000 customers’ cars every year. We operate our own car parks serving Gatwick, Manchester and Birmingham airports as well as offering other airport parking options at all major airports. With 4.5 out of 5 customer satisfaction and voted as ‘Best airport parking company’ at the British Travel Awards for 11 consecutive years, you’re in the best hands with APH.
The Science Behind specialise in integrating cutting-edge non-invasive neurostimulation and neuroimaging technologies and services to enhance Phase I clinical trials.
Innovatively applying techniques such as transcranial magnetic stimulation (TMS), quantitative sensory testing (QST) and electroencephalography (EEG), either independently or in combination with cognitive or physiological assessments, The Science Behind excels in addressing crucial questions related to target engagement, dose response and the timing of efficacy.
Our approach provides information on how a drug impacts various aspects of central nervous system function. This deeper insight into the neural mechanisms of drug action in humans serves to guide the development of new treatments, potentially enhancing their prospects for success in future clinical trials.
TheraCryf is a clinical stage drug development company focussed on the development of sulforaphane-based compounds, a new class of pharmaceuticals which are synthesised in a proprietary, well-tolerated, stable formulation.
There is a comprehensive intellectual property package over this technology, covering novel compositions and manufacturing methods.
TheraCryf exploits sulforaphane’s activity in three distinct disease-relevant cellular pathways; inhibition of pSTAT3, of importance in controlling cancer metastases, up-regulation of Nrf2, a therapeutic target associated with a broad range of diseases which are characterised by excessive oxidative stress, and inflammation and inhibition of SHP2, a target that has relevance in a number of solid tumours and haematological cancers.
